

## Product datasheet for **TL501709V**

### **Pou4f1 Mouse shRNA Lentiviral Particle (Locus ID 18996)**

#### **Product data:**

<b>Product Type:</b>	shRNA Lentiviral Particles
<b>Product Name:</b>	Pou4f1 Mouse shRNA Lentiviral Particle (Locus ID 18996)
<b>Locus ID:</b>	18996
<b>Synonyms:</b>	Brn-3; Brn-3.0; Brn3; Brn3.0; Brn3a; E130119J07Rik
<b>Vector:</b>	pGFP-C-shLenti (TR30023)
<b>Format:</b>	Lentiviral particles
<b>Components:</b>	Pou4f1 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
<b>RefSeq:</b>	<a href="#">NM_011143</a> , <a href="#">NM_011143.1</a> , <a href="#">NM_011143.2</a> , <a href="#">NM_011143.3</a> , <a href="#">NM_011143.4</a>
<b>UniProt ID:</b>	<a href="#">P17208</a>
<b>Summary:</b>	Multifunctional transcription factor with different regions mediating its different effects (PubMed:10640682, PubMed:8621561, PubMed:9694219, PubMed:9722627). Acts by binding (via its C-terminal domain) to sequences related to the consensus octamer motif 5'-ATGCAAAT-3' in the regulatory regions of its target genes (PubMed:8621561, PubMed:17668438). Regulates the expression of specific genes involved in differentiation and survival within a subset of neuronal lineages. It has been shown that activation of some of these genes requires its N-terminal domain, maybe through a neuronal-specific cofactor (PubMed:12934100). Activates BCL2 expression and protects neuronal cells from apoptosis (via the N-terminal domain) (PubMed:9722627). Induces neuronal process outgrowth and the coordinate expression of genes encoding synaptic proteins (PubMed:8972215). Exerts its major developmental effects in somatosensory neurons and in brainstem nuclei involved in motor control. Stimulates the binding affinity of the nuclear estrogen receptor ESR1 to DNA estrogen response element (ERE), and hence modulates ESR1-induced transcriptional activity (PubMed:9448000). May positively regulate POU4F2 and POU4F3 (PubMed:8876243). Regulates dorsal root ganglion sensory neuron specification and axonal projection into the spinal cord (PubMed:22326227). Plays a role in TNFSF11-mediated terminal osteoclast differentiation (PubMed:17668438). Negatively regulates its own expression interacting directly with a highly conserved autoregulatory domain surrounding the transcription initiation site (PubMed:12441296).[UniProtKB/Swiss-Prot Function]



[View online »](#)

<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .
<b>Performance Guaranteed:</b>	<p>OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.</p> <p>For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).</p>